Commentary
The meta-analysis by Vollenweider and colleagues finds that antibiotics reduce treatment failure in outpatients and inpatients alike, yet emphasizes a sensitivity analysis limited to currently used antibiotics that yielded similar relative risks but lacked power to demonstrate statistical significance. This sensitivity analysis seems somewhat arbitrary if antibiotic efficacy in COPD exacerbations can be attributed to bacterial killing, as seems most likely, and because it included some antibiotics no longer widely used for COPD due to changing antimicrobial resistance patterns. Moreover, in clinical practice, inpatient and outpatient exacerbations may be hard to distinguish objectively, as the threshold for hospital admission is influenced by clinician judgment and patient preferences. The 1987 study by Anthonisen and colleagues (1) classified exacerbations based on increase in characteristic symptoms (sputum volume, sputum purulence, and dyspnea) and observed that antibiotics seemed beneficial in patients who exhibited ≥ 2 of the above symptoms. Although based on this single trial, the Anthonisen criteria have widely influenced clinical management of COPD exacerbations. Although a meta-analysis of antibiotics in patients who meet these criteria would be invaluable, most trials have not stratified results based on these criteria, probably in part because they lacked the power to do so meaningfully. Future studies are needed to validate these criteria and other biomarkers as predictors of antibiotic efficacy in COPD. Current international guidelines, updated in February 2013 (2), recommend antibiotics for COPD exacerbations in patients who have ≥ 2 of the 3 cardinal symptoms or who require invasive or noninvasive ventilation. These guidelines are compatible with the meta-analysis evidence and provide an appropriate basis for current practice.
Matthew 
Review scope
Included studies compared ≥ 2 days of daily antibiotics with placebo in patients with acute COPD exacerbations. Studies had to include > 90% of COPD patients who were > 40 years of age; trials of clinically diagnosed COPD had to include ≥ 90% of patients with a history of smoking. Studies of patients with acute bronchitis, pneumonia, asthma, or bronchiectasis were excluded. Outcomes included treatment failure (no symptom resolution or deterioration after treatment, or death due to exacerbation or medication including study antibiotics) at 7 days to 1 month, mortality, and adverse events.
Review methods
Cochrane Airways Group Specialised Register of trials (Sep 2012), which includes studies identified from Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE/Excerpta Medica, CINAHL, AMED, PsycINFO, and hand-searches of respiratory journals and meeting abstracts; and reference lists of included randomized controlled trials (RCTs) and other systematic reviews were searched for placebo-controlled randomized trials. Authors of RCTs, pharmaceutical companies that produce antibiotics, and ClinicalTrials.gov were contacted. 16 RCTs (n = 2068) met the selection criteria: 9 included outpatients, 6 included inpatients, and 1 included patients admitted to a medical intensive care unit (ICU). Trial size ranged from 19 to 310 patients. 56% of studies adequately reported allocation concealment and blinding of outcome assessment.
Main results
Antibiotics reduced the number of patients with treatment failure overall (Table) , and in subgroups of outpatients (risk ratio [RR] 0.75, 95% CI 0.60 to 0.94), inpatients (RR 0.77, CI 0.65 to 0.91), and patients in the ICU (RR 0.19, CI 0.08 to 0.45). Meta-analysis showed that current antibiotics only (amoxicillin-clavulanic acid, trimethoprim/sulphamethoxazole, doxycycline, and penicillin) reduced treatment failure overall and in inpatients but not in outpatients (Table) . Other main results are in the Table.
Conclusions
Antibiotics for acute chronic obstructive pulmonary disease exacerbations reduce treatment failure, but not mortality, and increase 
